Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis - PubMed
9 hours ago
- #Cognitive Impairment
- #Dulaglutide
- #Neurodegeneration Biomarkers
- This post hoc analysis of the REWIND trial examined associations between dulaglutide and Alzheimer's disease/dementia biomarkers and cognitive impairment.
- Overall, dulaglutide did not show significant effects on biomarkers (neurofilament light chain, phosphorylated tau217, glial fibrillary acidic protein) or substantive cognitive impairment in the entire participant group.
- However, participants with elevated neurofilament light chain (≥56 pg/mL) showed a significant dulaglutide-associated reduction in this biomarker after 2 years.
- Participants with elevated phosphorylated tau217 (≥25 pg/mL) had a reduced risk of substantive cognitive impairment when treated with dulaglutide.
- The study suggests limited effects of dulaglutide on certain biomarkers over 2 years and recommends longer follow-up to explore incretin-related cognitive changes.